Zimmer Biomet Holdings, Inc. · ZBH · FY2024 Q3 · Calendar Q4 2024

Zimmer Biomet: ERP Disruption Tempers Growth, Pipeline Remains Active

The quarter showed continued underlying growth alongside execution friction: management described approximately 4% constant-currency sales growth and a broad product pipeline, but ERP-related disruption contributed to a modest reduction in full-year guidance. The longer-term growth case therefore depends on resolving operational constraints while converting product launches and robotics into sustained demand.

Why did ZBH rise 5.7% after missing EPS estimates in FY2024 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $19.53B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $1.74 Consensus $1.75
EPS surprise -0.6% Reported versus consensus
Reported revenue $1.82B Consensus $1.80B
Revenue surprise +1.6% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +5.7% Event window
SPY move -0.3% Same window
Abnormal move +6.0% Stock minus SPY
Volume 2.5× Versus trailing sessions
Subsequent drift +2.0% Up to 20 sessions
ZBHSPY benchmark

Ask FN2 about ZBH FY2024 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior quarter's reaffirmed 2024 outlook, Zimmer Biomet lowered full-year guidance in Q3. Management said ERP-related impact had narrowed to 60–80 basis points of annual sales and expected normal shipping by year-end; Q3 sales still grew approximately 4%.

Guidance delta

Full-year 2024 guidance was modestly lowered to 4.25%–4.75% constant-currency revenue growth. Management cited a reduced but still material ERP impact, estimated at 60–80 basis points of annual sales. Prior-quarter guidance had been maintained.

Key takeaways

  • Q3 sales grew approximately 4% despite ERP implementation disruption, continuing a run of mid-single-digit growth according to the supplied analysis.
  • Management said ERP effects were diminishing and expected normal shipping by year-end.
  • The full-year 2024 constant-currency revenue growth outlook was lowered to 4.25%–4.75%.
  • Product initiatives highlighted include the Z1 hip system, Persona OsseoTi knee, ROSA robotics, HAMMR and the TMINI platform.
  • The call analysis identifies competition, currency pressure, China procurement conditions and supply execution as material watchpoints.

Management priorities

  • Complete the ERP transition and restore normal shipping.
  • Commercialize Z1 and HAMMR and broaden ROSA indications.
  • Advance the product pipeline, including Oxford Partial cementless knee and coated hip implants.
  • Expand robotic and navigation offerings, including TMINI for ambulatory surgery settings.
  • Continue operational improvement and evaluate strategic M&A opportunities.

Follow ZBH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ZBH EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $2.15 Q4 '23 actual $2.20, beat Q1 '24 estimate $1.87 Q1 '24 actual $1.94, beat Q2 '24 estimate $1.99 Q2 '24 actual $2.01, beat Q3 '24 estimate $1.75 Q3 '24 actual $1.74, match Q2 '25 estimate $1.98 Q2 '25 actual $2.07, beat Q3 '25 estimate $1.87 Q3 '25 actual $1.90, beat Q4 '25 estimate $2.38 Q4 '25 actual $2.42, beat Q1 '26 estimate $1.86 Q1 '26 actual $2.09, beat Q2 '26 estimate $2.01 Q2 '26 actual $2.07, beat Q3 '26 estimate $1.88 Q3 '26 actual $1.90, beat Q4 '26 estimate $2.51 Q1 '27 estimate $2.09
Show less

Analyst Consensus ?

ConsensusHold42 ratings
Bullish1842.8%
Neutral2354.8%
Bearish12.4%

Analyst 52W Price Targets

$101.1Current
$83Low
$120.55Average
$180High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Equal Weight Equal WeightMaintainNov 9, 2026
Wells Fargo Equal Weight Equal WeightMaintainNov 5, 2026
UBS Buy BuyMaintainNov 5, 2026
RBC Capital Outperform OutperformMaintainNov 5, 2026
JP Morgan Neutral NeutralMaintainNov 5, 2026
Show 37 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $101.1. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Wells FargoLarry Biegelsen$123$101.41 +21.7%Nov 17, 2026
Stifel NicolausRick Wise$140$103.21 +38.5%Nov 16, 2026
Truist FinancialRichard Newitter$114$106.85 +12.8%Nov 5, 2026
Stifel NicolausRick Wise$125$110.15 +23.6%Nov 4, 2026
JefferiesMatthew Taylor$120$110.15 +18.7%Nov 4, 2026
See 74 more

Track every rating change on ZBH the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Historical context

All ZBH earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ZBH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
  3. Polygon adjusted daily market bars · 2026-11-16T11:56:05.557420+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-16T11:56:05.554562+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-16. For educational purposes only; not investment advice.